Verastem (VSTM)
(Delayed Data from NSDQ)
$6.08 USD
-0.09 (-1.46%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $6.08 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth F Momentum F VGM
Fundamental Charts
About Market Cap
As of the previous market close, Verastem, Inc. has a market cap of $339.04M, which represents its share price of $6.17 multiplied by its outstanding shares number of 54.95M. As a small-cap company, VSTM's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
VSTM 6.08 -0.09(-1.46%)
Will VSTM be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for VSTM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VSTM
Earnings Preview: Verastem (VSTM) Q2 Earnings Expected to Decline
Tempus AI's 89% Genomics Surge: Will the Momentum Keep Building?
VSTM: What are Zacks experts saying now?
Zacks Private Portfolio Services
VSTM Stock Soars 22% in a Month on Ovarian Cancer Combo Drug Approval
Verastem Oncology to Report Q1 Earnings: What's in the Cards?
Top Cancer Stocks to Buy to Boost Your Portfolio's Health
Other News for VSTM
Verastem Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025 | VSTM ...
Verastem Oncology gets FDA fast track status for cancer drug
Verastem Oncology Granted Fast Track Designation for VS-7375 for the Treatment of KRAS ...
Verastem: The Market Is Ignoring The Progress
Verastem (VSTM) Reports Promising Phase 2 Trial Results in Ovarian Cancer | VSTM Stock News